Tesamorelin — Safety, Research, Risks & Legal Status

Not medical advice. Tesamorelin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Egrifta, TH9507, tesamorelin acetate
Category	Peptide
fda_approved_for_hiv_lipodystrophy_only	Approved use is restricted to visceral fat reduction in HIV patients; all other uses are off-label or unapproved
d_amino_acid_stabilization	The D-amino acid at the N-terminus increases stability; duration of action is longer than native GHRH
wada_banned	Prohibited at all times in sport as a GHRH analog
US legal status	Tesamorelin (Egrifta) is FDA-approved in the United States as a prescription drug to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Outside that approved indication it is used off-label or sold as a research chemical, neither of which carries FDA approval. It is prohibited at all times in sport under the WADA list.

What is Tesamorelin?

Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates pituitary release of growth hormone. It is the active ingredient in the prescription product Egrifta. The addition of a D-amino acid at the N-terminus makes it more resistant to enzymatic degradation, giving it a longer half-life than native GHRH.

How it works

Tesamorelin binds to GHRH receptors on anterior pituitary somatotroph cells, mimicking the natural stimulatory effect of endogenous GHRH on growth hormone synthesis and secretion. The D-amino acid modification confers resistance to peptidase degradation, extending its circulating half-life to approximately 26 minutes compared to less than 2 minutes for native GHRH. This longer duration allows for once-daily or twice-daily dosing and stronger sustained GH elevations.

Background & history

Tesamorelin was developed in the 1990s and studied as a potential therapeutic for age-related GH decline and metabolic dysfunction. It was approved by the FDA in 2010 as Egrifta specifically for visceral lipodystrophy in HIV patients, marking the first FDA-approved GH secretagogue. Its approval was based on controlled trials demonstrating significant reductions in visceral fat in this population.

What the research says

Controlled human trials report that tesamorelin reduces visceral adipose tissue and raises IGF-1 in people with HIV-associated lipodystrophy, which is the basis of its approval. Studies also report it can lower triglycerides, and small studies have examined effects on liver fat and cognition, but evidence outside the approved population is more limited. Some reports suggest it may improve lean mass and metabolic parameters in specific contexts, though broader anti-aging use lacks robust evidence.

Reported effects

Reported reduction in visceral (abdominal) fat in studied populations
Studied increases in IGF-1 levels
Reported reductions in triglycerides in some trials
Studied effects on liver fat in early research
Reported lean mass preservation or increases in some studies
Studied cognitive and neurological effects in preliminary research

Dosing & administration (informational)

In clinical trials and approved use, tesamorelin has been administered as a subcutaneous injection of 2 milligrams once daily, typically in the evening. Studies of visceral adiposity reduction have examined durations of 6 months to 1 year, with most benefit observed within the first 6 months of treatment.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Injection carries risks of pain, swelling, redness, and injection-site reactions, plus infection risk with poor technique
Raising growth hormone and IGF-1 can cause insulin resistance, elevated blood glucose, fluid retention, and joint or muscle pain
Elevated GH and IGF-1 are a theoretical cancer concern, and the label cautions against use in people with active malignancy
Prohibited at all times in sport under the WADA list
Non-pharmaceutical research-chemical sources may be impure or mislabeled and lack the quality controls of the approved drug
Carpal tunnel syndrome and other compression neuropathies possible with sustained GH elevation

Drug & supplement interactions

Somatostatin and SST analogs suppress tesamorelin's GH-releasing activity
Glucocorticoids at high doses reduce endogenous GH secretion and may blunt response
Beta-adrenergic blockers can blunt GH secretion and reduce tesamorelin efficacy
Concurrent use with other GH secretagogues not well studied; combinations not standard

Who should avoid it

Active malignancy or prior cancer history (IGF-1 elevation is a growth-signal risk)
Uncontrolled diabetes or severe baseline glucose dysregulation
Sleep apnea of moderate to severe degree
Acute sepsis or critical illness
Severe thyroid hormone deficiency without replacement

How it is commonly combined

In research settings, tesamorelin has been combined with other GH secretagogues or metabolic modulators, but such combinations are not standard clinical practice and carry additive risks. Synergistic combinations are not well characterized in humans.

Legal & regulatory. Tesamorelin (Egrifta) is FDA-approved in the United States as a prescription drug to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Outside that approved indication it is used off-label or sold as a research chemical, neither of which carries FDA approval. It is prohibited at all times in sport under the WADA list.

Quality & harm reduction

T
h
e
a
p
p
r
o
v
e
d
d
r
u
g
E
g
r
i
f
t
a
i
s
t
h
e
o
n
l
y
q
u
a
l
i
t
y
-
a
s
s
u
r
e
d
s
o
u
r
c
e
;
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
m
a
t
e
r
i
a
l
s
h
o
u
l
d
b
e
t
r
e
a
t
e
d
w
i
t
h
c
a
u
t
i
o
n
a
n
d
r
e
q
u
i
r
e
s
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
.
L
o
o
k
f
o
r
H
P
L
C
a
n
d
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
d
a
t
a
.
E
n
d
o
t
o
x
i
n
t
e
s
t
i
n
g
,
s
t
e
r
i
l
e
r
e
c
o
n
s
t
i
t
u
t
i
o
n
,
a
n
d
c
o
l
d
s
t
o
r
a
g
e
m
a
t
t
e
r
f
o
r
i
n
j
e
c
t
a
b
l
e
p
e
p
t
i
d
e
s
t
o
m
a
i
n
t
a
i
n
s
t
r
u
c
t
u
r
a
l
i
n
t
e
g
r
i
t
y
a
n
d
s
t
e
r
i
l
i
t
y
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

What is tesamorelin approved for?

In the US it is FDA-approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Other uses are off-label or unapproved.

What dose is right for me?

We do not provide human dosing advice. Any use should be directed by a qualified clinician, and most non-HIV uses are unapproved.

Does it raise blood sugar?

Studies report that, like other GH-stimulating agents, it can increase blood glucose and reduce insulin sensitivity, which is why glucose monitoring is advised.

How does tesamorelin differ from sermorelin?

Tesamorelin is a D-amino acid-modified GHRH analog with extended half-life and is approved as a pharmaceutic for HIV lipodystrophy; sermorelin is a shorter GHRH peptide that was approved decades ago and is now mostly available via compounding.

Is Egrifta (the branded form) better than research-chemical tesamorelin?

Egrifta is FDA-manufactured with strict quality controls; research-chemical tesamorelin has no such assurance and carries contamination and mislabeling risks.

References & further reading

FDA: Egrifta (tesamorelin) prescribing information
PubMed: tesamorelin visceral adiposity HIV
PubMed: tesamorelin lipodystrophy clinical trial
WADA Prohibited List: GHRH and analogs
ClinicalTrials.gov: tesamorelin metabolic health